Why the study?
Sacubitril/valsartan reduces cardiovascular mortality and hospitalizations in HFrEF, with emerging evidence of potential antiarrhythmic effects.
Does sacubitril/valsartan improve reverse ventricular remodeling and reduce arrhythmic burden in a patient with an implantable cardioverter defibrillator?
Does sacubitril/valsartan improve reverse ventricular remodeling and reduce arrhythmic burden in a patient with an implantable cardioverter defibrillator?
Sacubitril/valsartan may promote reverse ventricular remodeling and reduce arrhythmic burden in patients with an ICD.
Case links remodeling to fewer arrhythmias on sacubitril/valsartan; hypothesis-generating and requires prospective confirmation.
Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
No takes yet. Share an insight, caveat, or question.
Corrado et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: